Shots: NICE has recommended Ajovy in its final appraisal document (FAD) to prevent migraine in patients with chronic migraine who have not responded to at least three prior preventive drug treatments The recommendation is based on a dossier submitted to NICE for a single technology appraisal (STA). Following the issuance of the FAD, NICE will […]Read More
Shots: The two P-II/III studies involve assessing of Ajovy vs PBO in patients with chronic and episodic migraine respectively The two P-II/III studies resulted in meeting its 1EPs and 2EPs and is well tolerated. The results will serve as a basis to file MAA for PMDA’s approval in Japan Ajovy is the first and only […]Read More
Shots: AJOVY (remanezumab-vfrm) is evaluated in two P-III trial enrolling patients with disabling migraine, administering AJOVY alone and in combination with oral preventive treatments, showing reduction in monthly migraine days in 12 wks. duration having injection site reactions as adverse effects The US Wholesale Acquisition Cost (WAC) of AJOVY for monthly and the quarterly dose […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
